Generation and Characterization of a Nanobody Against SARS-CoV.
The sudden emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has caused global panic in 2003, and the risk of SARS-CoV outbreak still exists. However, no specific antiviral drug or vaccine is available; thus, the development of therapeutic antibodies against SARS-CoV is needed. In this study, a nanobody phage-displayed library was constructed from peripheral blood mononuclear cells of alpacas immunized with the recombinant receptor-binding domain (RBD) of SARS-CoV. Four positive clones were selected after four rounds of bio-panning and subjected to recombinant expression in E. coli. Further biological identification demonstrated that one of the nanobodies, S14, showed high affinity to SARS-CoV RBD and potent neutralization activity at the picomole level against SARS-CoV pseudovirus. A competitive inhibition assay showed that S14 blocked the binding of SARS-CoV RBD to either soluble or cell-expressed angiotensin-converting enzyme 2 (ACE2). In summary, we developed a novel nanobody targeting SARS-CoV RBD, which might be useful for the development of therapeutics against SARS.
['Li|Jiang-Fan|JF|', 'He|Lei|L|', 'Deng|Yong-Qiang|YQ|', 'Qi|Shu-Hui|SH|', 'Chen|Yue-Hong|YH|', 'Zhang|Xiao-Lu|XL|', 'Hu|Shi-Xiong|SX|', 'Fan|Rui-Wen|RW|', 'Zhao|Guang-Yu|GY|http://orcid.org/0000-0002-0925-5216', 'Qin|Cheng-Feng|CF|http://orcid.org/0000-0002-0632-2807']
Nanobody Severe acute respiratory syndrome coronavirus (SARS-CoV) Receptor-binding domain (RBD) Neutralizing antibody